Song Zheng1,2,3,4, Yefei Shu2, Yidan Lu2,3, Yangcheng Sun2,4. 1. Department of Medical Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Zhejiang University School of Medicine Affiliated Hangzhou First People's Hospital, Hangzhou, Zhejiang, People's Republic of China. 2. Department of Medical Oncology, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China. 3. Department of Medical Oncology, Zhejiang Chinese Medical University Affiliated Hangzhou First Hospital, Hangzhou, Zhejiang, People's Republic of China. 4. Department of Medical Oncology, Nanjing Medical University Affiliated Hangzhou First People's Hospital, Hangzhou, Zhejiang, People's Republic of China.
Abstract
BACKGROUND: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. However, up to 40-50% of GISTs develop secondary resistance after an average of 24 months of imatinib treatment. It has been reported that autophagy can promote the survival of GIST cells and induce drug resistance. Presently, the specific mechanism of autophagy in GISTs with imatinib resistance is not clear. MATERIALS AND METHODS: The cell-counting kit (CCK)-8 method and flow cytometry were used for in vitro drug sensitivity testing and autophagy level detection. Detection of the apoptosis level was by flow cytometry with the annexin V Kit. Western blotting was used to analyze the role of autophagy and apoptosis in GIST cells with CQ alone, imatinib alone, or in combination, and to analyze MAPK pathway expression. In vitro results were confirmed by in vivo experiments using the mice model. Hematoxylin and eosin and immunohistochemical staining were used to detect the pathological characteristics and immunophenotype of the transplanted tumor. Detection of KIT and PDGFRA gene mutations in the transplanted imatinib-resistant GIST was done by denaturing high performance liquid chromatography (DHPLC) and direct sequencing. ERK and KIT expression and regulation levels were detected by Western blotting. RESULTS: In vitro and vivo experiments, the autophagy level of imatinib-resistant cells was higher than that of normal cells; CQ combined with imatinib can promote apoptosis by blocking autophagy of imatinib-resistant cells. In the meanwhile, we found that the phosphorylation level of ERK may be related to autophagy. CONCLUSION: Our data suggest that autophagy through the MAPK/ERK pathway may play a pivotal role in imatinib-resistant GIST proliferation. Moreover, combining an autophagy inhibitor with imatinib may be a potential valuable strategy in overcoming acquired resistance in GIST patients.
BACKGROUND: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. However, up to 40-50% of GISTs develop secondary resistance after an average of 24 months of imatinib treatment. It has been reported that autophagy can promote the survival of GIST cells and induce drug resistance. Presently, the specific mechanism of autophagy in GISTs with imatinib resistance is not clear. MATERIALS AND METHODS: The cell-counting kit (CCK)-8 method and flow cytometry were used for in vitro drug sensitivity testing and autophagy level detection. Detection of the apoptosis level was by flow cytometry with the annexin V Kit. Western blotting was used to analyze the role of autophagy and apoptosis in GIST cells with CQ alone, imatinib alone, or in combination, and to analyze MAPK pathway expression. In vitro results were confirmed by in vivo experiments using the mice model. Hematoxylin and eosin and immunohistochemical staining were used to detect the pathological characteristics and immunophenotype of the transplanted tumor. Detection of KIT and PDGFRA gene mutations in the transplanted imatinib-resistant GIST was done by denaturing high performance liquid chromatography (DHPLC) and direct sequencing. ERK and KIT expression and regulation levels were detected by Western blotting. RESULTS: In vitro and vivo experiments, the autophagy level of imatinib-resistant cells was higher than that of normal cells; CQ combined with imatinib can promote apoptosis by blocking autophagy of imatinib-resistant cells. In the meanwhile, we found that the phosphorylation level of ERK may be related to autophagy. CONCLUSION: Our data suggest that autophagy through the MAPK/ERK pathway may play a pivotal role in imatinib-resistant GIST proliferation. Moreover, combining an autophagy inhibitor with imatinib may be a potential valuable strategy in overcoming acquired resistance in GIST patients.
Authors: Anu Gupta; Srirupa Roy; Alexander J F Lazar; Wei-Lien Wang; John C McAuliffe; David Reynoso; James McMahon; Takahiro Taguchi; Giuseppe Floris; Maria Debiec-Rychter; Patrick Schoffski; Jonathan A Trent; Jayanta Debnath; Brian P Rubin Journal: Proc Natl Acad Sci U S A Date: 2010-07-26 Impact factor: 11.205
Authors: Kirsten L Bryant; Clint A Stalnecker; Daniel Zeitouni; Jennifer E Klomp; Sen Peng; Andrey P Tikunov; Venugopal Gunda; Mariaelena Pierobon; Andrew M Waters; Samuel D George; Garima Tomar; Björn Papke; G Aaron Hobbs; Liang Yan; Tikvah K Hayes; J Nathaniel Diehl; Gennifer D Goode; Nina V Chaika; Yingxue Wang; Guo-Fang Zhang; Agnieszka K Witkiewicz; Erik S Knudsen; Emanuel F Petricoin; Pankaj K Singh; Jeffrey M Macdonald; Nhan L Tran; Costas A Lyssiotis; Haoqiang Ying; Alec C Kimmelman; Adrienne D Cox; Channing J Der Journal: Nat Med Date: 2019-03-04 Impact factor: 53.440
Authors: Hezhe Lu; Shujing Liu; Gao Zhang; Yueyao Zhu; Dennie T Frederick; Yi Hu; Wenqun Zhong; Sergio Randell; Norah Sadek; Wei Zhang; Gang Chen; Chaoran Cheng; Jingwen Zeng; Lawrence W Wu; Jie Zhang; Xiaoming Liu; Wei Xu; Clemens Krepler; Katrin Sproesser; Min Xiao; Benchun Miao; Jianglan Liu; Claire D Song; Jephrey Y Liu; Giorgos C Karakousis; Lynn M Schuchter; Yiling Lu; Gordon Mills; Yusheng Cong; Jonathan Chernoff; Jun Guo; Genevieve M Boland; Ryan J Sullivan; Zhi Wei; Jeffrey Field; Ravi K Amaravadi; Keith T Flaherty; Meenhard Herlyn; Xiaowei Xu; Wei Guo Journal: Nature Date: 2017-09-27 Impact factor: 49.962